Previous experiments with the clinically used ALOX5 inhibitor zileuton suggested that inactivation of endogenous leukotriene biosynthesis attenuated the inflammatory symptoms in different animal colitis models [36,45]. This evidence concerns the gene ALOX5 and colitis.